BInno2scalek01 | Scale Business and Technology to Impact on Disease Research by with Lossless and Efficient Data Analysis

Summary
Aren’t we expecting from disease research that all available data is being used? Yes! Yet one of the biggest hurdles is the data variety when to studying underlying mechanisms or prioritizing targets for novel treatments. Ultimately stalling projects and resulting in low output and quality. knowing01 GmbH is a deep tech software company founded in 2020 in Munich, Germany that gives Life Scientists full control of all their research data. Dr. Nikola Müller (founder and CEO) has spearheaded the project since 2014, when the idea budded during her academic research at Helmholtz Munich. The knowing01 solution is a software-as-a-service (SaaS) suite that allows the user to connect and explore omics data no matter their biodata type. Our innovative knowledge-graph based translation approach empowers scientists to run analyses across data types and compare different sets in their biological context. We additionally offer on client premise, licensed software. Our next challenging milestone is to scale a) by innovating the business and b) by having a critical assessment of the technology. We aim to exploit our niche market position. We are specifically aiming to be attractive to key partners that offer our together with their own services. We need scale our infrastructure and database-related technologies alongside with the business. Only both will allow us to future-proof our business paving the way for a sustainable business. Dr. Nikola Müller will profit from being part of the Women Leadership Program by sharpening negotiation skills, learning how to improve public visibility and finally, getting into potent female-friendly investor networks. Compared to classical IT, biotech or digital health companies, our offering opens a yet unexplored niche, which is why we will enormously profit from the Women TechEU grant. The non-dilutive funding will be critical of us being able to support the scale-developments to be able to move our business forward.
Results, demos, etc. Show all and search (1)
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101072224
Start date: 01-07-2022
End date: 30-06-2023
Total budget - Public funding: - 75 000,00 Euro
Cordis data

Original description

Aren’t we expecting from disease research that all available data is being used? Yes! Yet one of the biggest hurdles is the data variety when to studying underlying mechanisms or prioritizing targets for novel treatments. Ultimately stalling projects and resulting in low output and quality. knowing01 GmbH is a deep tech software company founded in 2020 in Munich, Germany that gives Life Scientists full control of all their research data. Dr. Nikola Müller (founder and CEO) has spearheaded the project since 2014, when the idea budded during her academic research at Helmholtz Munich. The knowing01 solution is a software-as-a-service (SaaS) suite that allows the user to connect and explore omics data no matter their biodata type. Our innovative knowledge-graph based translation approach empowers scientists to run analyses across data types and compare different sets in their biological context. We additionally offer on client premise, licensed software. Our next challenging milestone is to scale a) by innovating the business and b) by having a critical assessment of the technology. We aim to exploit our niche market position. We are specifically aiming to be attractive to key partners that offer our together with their own services. We need scale our infrastructure and database-related technologies alongside with the business. Only both will allow us to future-proof our business paving the way for a sustainable business. Dr. Nikola Müller will profit from being part of the Women Leadership Program by sharpening negotiation skills, learning how to improve public visibility and finally, getting into potent female-friendly investor networks. Compared to classical IT, biotech or digital health companies, our offering opens a yet unexplored niche, which is why we will enormously profit from the Women TechEU grant. The non-dilutive funding will be critical of us being able to support the scale-developments to be able to move our business forward.

Status

SIGNED

Call topic

HORIZON-EIE-2021-SCALEUP-01-03

Update Date

09-02-2023
Images
No images available.
Geographical location(s)